Laurus Labs Ltd. News and Updates

Name: Latest research reports of Laurus Labs Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Laurus Labs Ltd.
Rating: 5
Author: Motilal Oswal

Keep track of all breaking news on Laurus Labs Ltd. from all sources in a single place.

Load latest

Laurus Labs Ltd.

26 Apr 2024

588.80

0.35%

Laurus Labs Q4 Results Review - Product Mix, Reduced Operating Leverage Hurt Profitability: Motilal Oswal

NDTV Profit

Benefits from investments made over FY22-24 to gain momentum

Laurus Labs Ltd. has gained 34.57% in the last 1 Year

Laurus Labs Q4 Results: Profit Drops 28%, Misses Estimates

NDTV Profit | 25 Apr 2024

Laurus Labs Ltd.

25 Apr 2024

588.80

0.35%

Laurus Labs Results Earnings Call for Q4FY24

Conference Call with Laurus Labs Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript

audio

Laurus Labs Ltd.

25 Apr 2024

588.80

0.35%

to see Rapid results content

Laurus Labs Ltd.

25 Apr 2024

588.80

0.35%

Product mix and reduced operating leverage hurt profitability

Buy: Laurus Labs Ltd.

Target

Motilal Oswal

Laurus Labs (LAURUS) delivered better-than-expected revenue in 4QFY24.
However, EBITDA/PAT missed our estimates due to lower sales in the CDMO
segment and weak pricing in the other API segment.

Number of FII/FPI investors increased from 237 to 259 in Mar 2025 qtr.

Laurus Labs Ltd.

31 Jan 2024

588.80

0.35%

Accumulate Laurus Labs; target of Rs 424: KR Choksey

Moneycontrol

KR Choksey recommended accumulate rating on Laurus Labs with a target price of Rs 424 in its research report dated January 29, 2024.

KRChoksey released a Accumulate report for Laurus Labs Ltd. with a price target of 687.0 on 30 Apr, 2025.

Laurus Labs Ltd.

29 Jan 2024

588.80

0.35%

Buy Laurus Labs; target of Rs 440: Motilal Oswal

Moneycontrol

Motilal Oswal is bullish on Laurus Labs recommended buy rating on the stock with a target price of Rs 440 in its research report dated January 25, 2024.

Number of FII/FPI investors increased from 237 to 259 in Mar 2025 qtr.

Laurus Labs Ltd.

29 Jan 2024

588.80

0.35%

First Light | Bajaj Auto, TVS Motor, SBI Card, Laurus Labs, Cipla, Mahanagar Gas, DCB Bank, SBI Life

Sell: Laurus Labs Ltd.

BOB Capital Markets Ltd.

BJAUT: Healthy revival but priced in; downgrade to SELL. TVSL: On a fast track raise to BUY. SBICARD: Asset quality concerns persist; downgrade to HOLD. LAURUS: Challenges galore cut to SELL. CIPLA: Healthy revenue growth, strong margins. MAHGL: Volume growth accelerating, reiterate BUY. DCBB: NII sequentially flat on high interest cost. SBILIFE: ULIP-led growth; maintains market leadership

Laurus Labs Ltd. is trading below its 30 day SMA of 612.6

Laurus Labs Ltd.

29 Jan 2024

588.80

0.35%

Momentum in FDF, Bio and Oncology APIs strong, to aid in growth

Accumulate: Laurus Labs Ltd.

Target

KRChoksey

Laurus Labs’ revenue declined 22.6% Y-o-Y (-2.4% Q-o-Q) to Rs. 11,949 Mn (vs. our estimate of Rs. 12,669, miss of 5.7%) in Q3FY24. The generic API sales declined at 9.2% Y-o-Y (-8.7% Q-o-Q) to Rs. 5,740 Mn (vs. our estimate of Rs. 6,627 Mn, a miss 13.4%) due to high base effect as anticipated with the loss of Paxlovid opportunity in the current period, that took place during Q4FY22-Q3FY23.